Id: acc1863
Group: 2sens
Protein: HSP70
Gene Symbol: HSPA1A
Protein Id: P0DMV8
Protein Name: HS71A_HUMAN
PTM: methylation
Site: Arg447
Site Sequence: VLIQVYEGERAMTKDNNLLGR
Disease Category: Cancer
Disease: Pancreas Cancer
Disease Subtype:
Disease Cellline: MIA PaCa-2
Disease Info:
Drug: gemcitabine
Drug Info: "Gemcitabine is a pyrimidine nucleoside analog antimetabolite and antineoplastic agent that inhibits DNA synthesis and repair, leading to autophagy and apoptosis, and is used in the treatment of various solid tumors including non-small cell lung cancer, pancreatic cancer, breast cancer, and ovarian cancer. "
Effect: resist
Effect Info: Overexpression of PRMT1 (which can be inhibited by DB75 and TC - E5003) increases arginine methylation of HSP70 and protects cancer cells from apoptosis induced by cellular stress and the therapeutic drug gemcitabine.
Note:
Score: 5.0
Pubmed(PMID): 32699135
Sentence Index:
Sentence:

Sequence & Structure:

MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIPPAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKYKAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANTLAEKDEFEHKRKELEQVCNPIISGLYQGAGGPGPGGFGAQGPKGGSGSGPTIEEVD

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
HSPA1A CD24FC Heat shock 70 kDa protein 1A/1B inhibitor 3 Completed COVID-19 ClinicalTrials
HSPA1A CD24FC Heat shock 70 kDa protein 1A/1B inhibitor 1 Terminated neoplasm ClinicalTrials
HSPA1A CD24FC Heat shock 70 kDa protein 1A/1B inhibitor 1 Withdrawn metastatic melanoma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 631 D Pulmonary hypertension Phosphorylation 30485823
K 126 U Breast cancer Acetylation 30352233
K 561 U Breast cancer/tumor/carcinoma Methylation 26448330
K 561 U Ovarian cancer/carcinoma Methylation 26448330
K 561 U Adenocarcinoma Methylation 22990868
K 561 U Bladder cancer Methylation 22990868
K 561 U Cancer Methylation 22990868
K 561 U Cervical cancer/carcinoma Methylation 22990868
K 561 U Colon cancer/carcinoma Methylation 22990868
K 561 U Hepatocellular carcinoma/hepatocarcinoma/hepatoma Methylation 22990868
K 561 U Lung adenocarcinoma Methylation 22990868
K 561 U Lung cancer/carcinoma Methylation 22990868

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: